Key findings indicate that AMSCs (1) suppress inflammatory factors; (2) ameliorate pulmonary hemorrhage, edema, and alveolar wall hyperplasia; and (3) mitigate tissue damage via the dual inhibition of TLR4/NF-κB/MAPK and TGF-β/Smad signaling cascades. The gene discussed is NFKB1; the disease is Pulmonary hemorrhage.